Edwards Lifesciences Corp (EW) appears to be in a volatile phase, as early reports of strong sales growth and a promising PASCAL System trial in heart valve repair signify progress. However, the company has faced challenging situations such as a pending class-action lawsuit and a drop from the Russell 1000 Growth Index. Although recent years have not been profitable for EW investors, new studies are positioning EW as a potential game-changer in areas like tricuspid valve repair and heart failure treatment. On a brighter note, sales forecasts for 2025 have been raised along with positive analyst outlooks despite fluctuations in stock prices. Further controversy arises through investor class action, and news of global layoffs at the company. The recent receipt of the CE Mark for their SAPIEN M3 as the world’s first transfemoral transcatheter mitral valve replacement system provides a ray of hope for the corporation.
Edwards Lifesciences Corp EW News Analytics from Thu, 25 Jul 2024 07:00:00 GMT to Thu, 03 Jul 2025 22:25:17 GMT -
Rating -2
- Innovation -4
- Information 7
- Rumor -3
